AndroGel Cost in Kansas 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Is the Cash Price for AndroGel in Kansas in 2026?

The retail cash price for AndroGel 1.62% at Kansas pharmacies averages about $510 per month in 2026, consistent with AbbVie's manufacturer list price. Prices vary by pharmacy and formulation. AndroGel 1% packets tend to carry a similar sticker price, while the pump formulation of AndroGel 1.62% may differ by a few dollars depending on the dispensing pharmacy.

Testosterone replacement therapy corrects the serum testosterone deficiency documented in male hypogonadism. The Endocrine Society clinical practice guideline defines biochemical hypogonadism as a consistently low morning total testosterone below 300 ng/dL confirmed on two separate measurements [1]. Treatment with topical testosterone gel, including AndroGel, raises serum testosterone into the mid-normal range for most patients within three to four weeks of initiating therapy [2].

The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials in men aged 65 or older with low testosterone (below 275 ng/dL), found that testosterone treatment for one year produced statistically significant improvements in sexual function, bone mineral density, and walking distance compared with placebo [3]. Those findings, published in the New England Journal of Medicine and JAMA, gave prescribers a rigorous evidence base for TRT that has shaped prescribing guidelines ever since.

At $510 per month cash, Kansas patients who pay out of pocket face roughly $6,120 per year. That figure does not include lab monitoring costs, which the Endocrine Society recommends at 3 and 6 months after initiation and then annually [1].

GoodRx coupons at major Kansas chains, including CVS, Walgreens, Dillons Pharmacy, and Walmart, can bring the retail price down to approximately $380 to $460 per month depending on the specific pharmacy location and the formulation dispensed [4]. Prices shift with wholesaler contracts, so checking the GoodRx portal at the time of fill gives the most accurate figure.

Does Kansas Medicaid Cover AndroGel?

Kansas Medicaid (KanCare) does not cover AndroGel or brand-name testosterone gels for male hypogonadism as of 2026. Coverage is restricted to patients whose testosterone deficiency is documented as a direct complication of type 2 diabetes-related hypogonadism under specific KanCare prior-authorization criteria [5]. For the majority of Kansas men with primary or age-related hypogonadism, AndroGel remains a non-covered benefit.

KanCare is administered through three managed care organizations: Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan. Each MCO applies the statewide formulary restrictions. A patient seeking coverage would need to submit a prior authorization documenting the diabetes-related indication, along with two low serum testosterone measurements and a confirming clinical note from a physician or advanced practice provider [5].

Medicare Part D coverage varies by plan. Some Part D plans do cover generic testosterone gel (not the branded AndroGel) after a prior authorization step. Patients enrolled in a Kansas Medicare Part D plan should check their plan's formulary tier before assuming no coverage exists.

The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011 specifically for the treatment of hypogonadism in adult males [6]. That approval history is relevant because some payers cite FDA-approved indications when adjudicating prior authorization requests.

Which Private Insurance Plans in Kansas Cover AndroGel?

Most commercial insurance plans available in Kansas list testosterone gel on their formularies, though the benefit almost always requires a prior authorization and places the drug on Tier 3 or Tier 4, which means higher cost-sharing. After prior authorization is approved, patient co-pays typically range from $60 to $150 per month depending on the plan design and whether the patient has met their deductible [7].

BCBS of Kansas, Cigna, Aetna, and United Healthcare commercial plans generally cover testosterone gel products, including generic versions, when prior authorization criteria are met. Those criteria typically require two documented morning serum testosterone values below 300 ng/dL, a clinical diagnosis of hypogonadism, and a note confirming the absence of contraindications such as prostate cancer or severe untreated benign prostatic hyperplasia [7].

Step therapy is common. Many Kansas commercial plans require a trial of generic testosterone gel (or testosterone cypionate injection) before authorizing the brand-name AndroGel. If generic testosterone 1% gel is clinically equivalent for a given patient, accepting that substitution usually cuts the co-pay to Tier 2 or even Tier 1 levels on most formularies.

The FDA's Orange Book confirms that several manufacturers market AB-rated generic testosterone 1% gel products that are therapeutically equivalent to AndroGel 1% [6]. Prescribers can note "dispense as written" to prevent substitution, but doing so removes the patient from most generic-tier pricing.

How Does the AbbVie Savings Card Work for Kansas Patients?

AbbVie offers the myAbbVie Assist program, which provides AndroGel at no cost to patients who meet income eligibility criteria and are uninsured or underinsured. For commercially insured patients who do not qualify for the patient assistance program, AbbVie separately offers a co-pay savings card that can reduce monthly cost-sharing to as low as $0 for eligible patients, up to a defined annual cap [8].

Kansas residents can apply online at AbbVie's patient assistance portal or by calling AbbVie directly. The program excludes patients whose primary coverage is a federal program, meaning Medicare and Medicaid beneficiaries cannot use the co-pay card. That exclusion affects a meaningful portion of older Kansas men, since testosterone deficiency prevalence rises with age.

Applying for the savings card requires proof of commercial insurance, a valid AndroGel prescription, and confirmation that the patient resides in the United States. Approval is typically granted at the point of application. Refill savings are applied automatically at the pharmacy using the card's BIN and PCN numbers.

The myAbbVie Assist patient assistance program, distinct from the co-pay card, covers the full cost of AndroGel for uninsured patients whose household income falls at or below 400 percent of the federal poverty level. Applications require income documentation and a physician signature [8].

Is Compounded Testosterone Gel Legal in Kansas?

Compounded testosterone gel is legal in Kansas when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Federal law under the Drug Quality and Security Act of 2013 defines 503A pharmacies as traditional compounding pharmacies that compound medications for individual patients based on a prescription [9].

Kansas pharmacies operating under the 503A designation may compound testosterone gel in strengths or bases not commercially available, provided the prescription is patient-specific and the compound is not a copy of a commercially available product without a documented clinical rationale. The Kansas State Board of Pharmacy oversees licensure and compliance for compounding pharmacies operating within the state.

The cost advantage is significant. Compounded testosterone gel from a Kansas 503A pharmacy averages about $120 per month, compared with the $510 retail cash price for brand-name AndroGel. That price difference, roughly $390 per month or $4,680 per year, drives many cash-pay patients toward compounded options [10].

Quality considerations matter. The FDA has noted that compounded preparations do not undergo the same pre-market review for safety, efficacy, and manufacturing quality as FDA-approved drugs [6]. Reputable compounding pharmacies hold Pharmacy Compounding Accreditation Board (PCAB) accreditation, and patients should verify that their compounding pharmacy carries that credential.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Federal and Kansas state law require a valid prescription from a DEA-registered practitioner for any compounded testosterone product, just as for the brand-name product [11].

Can Kansas Patients Get AndroGel Through Telehealth?

Telehealth prescribing of AndroGel is legal in Kansas as of 2026. Kansas enacted telehealth parity legislation, and the state Medical Practice Act permits licensed Kansas physicians and advanced practice providers to evaluate patients, order laboratory tests, and prescribe Schedule III controlled substances via synchronous video visit, provided a proper patient-provider relationship is established [12].

Federal rules relaxed during the COVID-19 public health emergency allowed prescribing of controlled substances via telemedicine without a prior in-person visit. The DEA's 2023 proposed rules and subsequent regulatory action left certain controlled substance prescribing via telemedicine in a transitional state through 2025, but testosterone (Schedule III) falls under frameworks that have allowed continued telehealth prescribing through registered telemedicine providers operating in compliance with DEA telemedicine rules [11].

HealthRX operates in Kansas. Patients complete an intake form, submit recent lab work (or order through a HealthRX-partnered lab draw near them), and meet with a licensed Kansas provider via video. If hypogonadism is confirmed, the provider can send a prescription electronically to the patient's preferred Kansas pharmacy or to a partnered compounding pharmacy.

The clinical workup before initiating testosterone therapy should include two morning total testosterone measurements, a complete blood count, hematocrit, PSA (in men over 40), and a discussion of fertility preservation, since exogenous testosterone suppresses spermatogenesis [1]. The Endocrine Society guideline recommends against initiating TRT in men who are actively trying to conceive [1].

How to Choose Between AndroGel, Generic Testosterone Gel, and Compounded Testosterone Gel in Kansas

Choosing the right formulation depends on insurance status, budget, and clinical preference. The table below outlines a practical decision framework for Kansas patients in 2026.

Insured patients with commercial coverage: Request prior authorization for generic testosterone 1% gel first. If the plan covers it at Tier 2, the monthly co-pay may be $30 to $80. Use brand-name AndroGel only if the prescriber documents a clinical reason generic gel is not appropriate. Apply the AbbVie co-pay card if the plan covers AndroGel and residual cost-sharing exceeds $0.

Uninsured patients below 400 percent FPL: Apply for the myAbbVie Assist patient assistance program for free brand-name AndroGel, or obtain a prescription for compounded testosterone gel at approximately $120 per month from a PCAB-accredited Kansas 503A pharmacy.

Uninsured patients above 400 percent FPL or ineligible for AbbVie assistance: Compounded testosterone gel at $120 per month is the most affordable legal option. Confirm the pharmacy's 503A status with the Kansas State Board of Pharmacy before filling.

Medicare or Medicaid patients: Check the Part D plan formulary for generic testosterone gel. Compounded testosterone may not be eligible for Part D reimbursement. Cash-pay compounded gel at $120 per month is a common fallback for Medicare patients whose plan does not cover testosterone products.

Clinical monitoring requirements remain the same regardless of which product is chosen. The Endocrine Society guideline specifies hematocrit monitoring at 3 to 6 months and annually, PSA monitoring per age-appropriate guidelines, and serum testosterone measurement 3 to 6 months after initiation to confirm target range achievement [1].

The Clinical Evidence Behind Testosterone Gel Therapy

The TTrials enrolled 788 men aged 65 or older with symptomatic hypogonadism across 12 U.S. sites and randomized them to testosterone gel or placebo gel for 12 months. The sexual function trial component showed a mean improvement of 2.64 points on the Psychosexual Daily Questionnaire sexual activity domain in the testosterone group versus 0.54 points with placebo (P<0.001) [3]. The mobility trial showed a modest but statistically significant improvement in 6-minute walking distance in the testosterone group [3].

A 2018 meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooling 156 randomized controlled trials (N=8,799) found that testosterone therapy produced significant improvements in sexual function, body composition, and bone mineral density compared with placebo, though cardiovascular outcomes remained less conclusively defined [13].

The FDA reviewed the cardiovascular signal associated with testosterone products in 2015 and required label updates stating that venous thromboembolism, including deep vein thrombosis and pulmonary embolism, has been reported in patients using testosterone products [6]. The FDA also required labeling regarding the potential for abuse and dependence as a Schedule III substance.

A 2023 NEJM paper reporting the TRAVERSE trial (N=5,246 men with hypogonadism and elevated cardiovascular risk, mean age 63.6 years) found that testosterone replacement therapy was non-inferior to placebo for the rate of major adverse cardiovascular events over a mean follow-up of 33 months [14]. That finding substantially clarified the cardiovascular risk picture that had concerned prescribers since the Vigen et al. JAMA paper in 2013.

Application technique affects serum levels. AndroGel should be applied to clean dry skin on the shoulders, upper arms, or abdomen (1.62% formulation only for abdomen). Patients should wash hands immediately after application and cover the application site to prevent transfer to women or children, which carries an FDA black box warning [6].

Monitoring Labs and Dosing Adjustments in Kansas Clinical Practice

AndroGel 1.62% is initiated at 40.5 mg testosterone per day (two pump actuations or two unit-dose packets). The prescriber adjusts the dose based on a serum testosterone drawn 2 to 8 hours after application, at least 14 days after the previous dose adjustment [6].

Target serum testosterone on gel therapy is generally 400 to 700 ng/dL when drawn at trough (immediately before the next application), though the Endocrine Society places the mid-normal range at 400 to 700 ng/dL for adult men [1]. Doses can be increased to 81 mg per day (four actuations) or decreased to 20.25 mg per day (one actuation) based on measured levels.

Hematocrit should remain below 54 percent. If hematocrit exceeds 54 percent, the dose should be reduced or therapy held temporarily until hematocrit normalizes, at which point a lower dose may be restarted [1]. Erythrocytosis is the most common dose-dependent adverse effect of testosterone gel therapy and requires clinical attention, particularly in older men or those with sleep apnea.

PSA should be measured at 3 to 6 months after initiation and then per age-appropriate prostate cancer screening guidelines. An increase in PSA greater than 1.4 ng/mL within 12 months of initiating testosterone therapy, or a PSA velocity greater than 0.4 ng/mL per year, warrants urological evaluation before continuing therapy [1].

Kansas providers ordering labs for TRT monitoring can use any CLIA-certified laboratory. Quest Diagnostics and LabCorp both operate patient service centers throughout Kansas, including Wichita, Overland Park, Kansas City, and Topeka.